JP6681387B2 - 糖尿病の慢性合併症において使用するためのｓｏｃｓ１由来ペプチド - Google Patents

糖尿病の慢性合併症において使用するためのｓｏｃｓ１由来ペプチド Download PDF

Info

Publication number
JP6681387B2
JP6681387B2 JP2017514978A JP2017514978A JP6681387B2 JP 6681387 B2 JP6681387 B2 JP 6681387B2 JP 2017514978 A JP2017514978 A JP 2017514978A JP 2017514978 A JP2017514978 A JP 2017514978A JP 6681387 B2 JP6681387 B2 JP 6681387B2
Authority
JP
Japan
Prior art keywords
diabetic
pharmaceutical composition
sequence
seq
retina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017514978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524727A (ja
JP2017524727A5 (enExample
Inventor
ヘスス、エギド、デ、ロス、リオス
カルメン、ゴメス、ゲレロ
ラファエル、シモ、カノンゲ
クリスティナ、エルナンデス、パスクアル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz
Original Assignee
Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz filed Critical Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz
Publication of JP2017524727A publication Critical patent/JP2017524727A/ja
Publication of JP2017524727A5 publication Critical patent/JP2017524727A5/ja
Application granted granted Critical
Publication of JP6681387B2 publication Critical patent/JP6681387B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2017514978A 2014-05-28 2015-05-27 糖尿病の慢性合併症において使用するためのｓｏｃｓ１由来ペプチド Expired - Fee Related JP6681387B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP201430796 2014-05-28
ES201430796A ES2552587B1 (es) 2014-05-28 2014-05-28 Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes
PCT/ES2015/070415 WO2015181427A1 (es) 2014-05-28 2015-05-27 Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes

Publications (3)

Publication Number Publication Date
JP2017524727A JP2017524727A (ja) 2017-08-31
JP2017524727A5 JP2017524727A5 (enExample) 2018-07-05
JP6681387B2 true JP6681387B2 (ja) 2020-04-15

Family

ID=53546661

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017514978A Expired - Fee Related JP6681387B2 (ja) 2014-05-28 2015-05-27 糖尿病の慢性合併症において使用するためのｓｏｃｓ１由来ペプチド

Country Status (13)

Country Link
US (2) US10532082B2 (enExample)
EP (1) EP3178485B1 (enExample)
JP (1) JP6681387B2 (enExample)
CN (1) CN107074922A (enExample)
BR (1) BR112016027936A2 (enExample)
CA (1) CA2950348A1 (enExample)
ES (2) ES2552587B1 (enExample)
HU (1) HUE041836T2 (enExample)
MX (1) MX369378B (enExample)
PL (1) PL3178485T3 (enExample)
PT (1) PT3178485T (enExample)
TR (1) TR201903509T4 (enExample)
WO (1) WO2015181427A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552587B1 (es) 2014-05-28 2017-01-18 Fundació Hospital Universitari Vall D'hebron-Institut De Recerca Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes
CN105315377A (zh) * 2015-12-07 2016-02-10 华东理工大学 带有穿膜肽的tcs融合蛋白、质粒及制备方法与应用
JP2019509277A (ja) * 2016-02-23 2019-04-04 武田薬品工業株式会社 疼痛の治療のためのβアレスチン―ニューロキニン１受容体相互作用の阻害剤
CN106349347B (zh) * 2016-10-25 2019-09-13 南通大学 一种小分子多肽、及其编码基因和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175971A1 (en) * 2001-12-28 2003-09-18 Geoffrey Lindeman Differentiation and/or proliferation modulating agents and uses therefor
AU2005220874B2 (en) * 2004-03-04 2010-12-23 Vanderbilt University Cell-penetrating SOCS polypeptides that inhibit cytokine-induced signaling
US7868158B2 (en) * 2004-07-19 2011-01-11 Baylor College Of Medicine Modulation of cytokine signaling regulators and applications for immunotherapy
JP5041231B2 (ja) 2005-02-15 2012-10-03 東亞合成株式会社 抗菌ペプチド及びその利用
EP1918297A4 (en) 2005-07-20 2010-03-10 Toagosei Co Ltd PEPTIDE INDUCING NEURONAL DIFFERENTIATION AND APPLYING THEREOF
WO2010151495A2 (en) 2009-06-26 2010-12-29 University Of Florida Research Foundation Inc. Materials and methods for treating and preventing viral infections
US20110229525A1 (en) * 2010-03-12 2011-09-22 Vanderbilt University Modulation of cytokine signaling
CN102921007B (zh) * 2011-08-09 2014-12-10 中国科学院上海生命科学研究院 防治胰岛素抵抗和糖尿病的方法和试剂
CN103173446A (zh) * 2011-12-26 2013-06-26 吕成伟 一种靶向干扰socs1基因的重组腺相关病毒载体的构建方法与应用
ES2552587B1 (es) 2014-05-28 2017-01-18 Fundació Hospital Universitari Vall D'hebron-Institut De Recerca Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes

Also Published As

Publication number Publication date
US20200138903A1 (en) 2020-05-07
JP2017524727A (ja) 2017-08-31
US20170209536A1 (en) 2017-07-27
PL3178485T3 (pl) 2019-07-31
MX2016015514A (es) 2017-05-04
ES2552587R1 (es) 2016-02-10
CA2950348A1 (en) 2015-12-03
TR201903509T4 (tr) 2019-04-22
BR112016027936A2 (pt) 2017-10-24
EP3178485B1 (en) 2018-12-12
HUE041836T2 (hu) 2019-05-28
ES2715412T3 (es) 2019-06-04
ES2552587A2 (es) 2015-11-30
PT3178485T (pt) 2019-03-22
CN107074922A (zh) 2017-08-18
EP3178485A1 (en) 2017-06-14
WO2015181427A1 (es) 2015-12-03
US10532082B2 (en) 2020-01-14
MX369378B (es) 2019-11-07
ES2552587B1 (es) 2017-01-18

Similar Documents

Publication Publication Date Title
Ristori et al. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of β-adrenoreceptor blockade
Kurihara et al. Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation
US20200138903A1 (en) Socs1-derived peptide for use in chronic complications of diabetes
Xiaohong et al. CFLAR is a critical regulator of cerebral ischaemia-reperfusion injury through regulating inflammation and endoplasmic reticulum (ER) stress
CN109937053B (zh) 用于治疗黄斑变性的含有mTOR抑制剂的药物组合物
Reid et al. Erythropoietin in diabetic retinopathy
JP2011513290A (ja) ＶＥＧＦｘｘｘｂの新規な使用
Basavarajappa et al. S1PR1 signaling attenuates apoptosis of retinal ganglion cells via modulation of cJun/Bim cascade and Bad phosphorylation in a mouse model of glaucoma
US7960345B2 (en) Angiogenesis inhibitor comprising meteorin as an active ingredient
US10519232B2 (en) Agents for use in the treatment of retinal inflammation
KR102411574B1 (ko) 망막 신경변성 질환의 국소 안구 치료를 위한 디펩티딜 펩티다제-4 저해제
Rau et al. Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis
Xu et al. EphA4/ephrinA3 reverse signaling induced Müller cell gliosis and production of pro-inflammatory cytokines in experimental glaucoma
US20190002517A1 (en) Neuropeptide y-derived peptides
Pacheco et al. Neuroprotective effect of exogenous galectin-1 in status epilepticus
Feng et al. Serum amyloid A aggravates endotoxin‐induced ocular inflammation through the regulation of retinal microglial activation
Kucuk et al. Therapeutic potential of erythropoietin in retinal and optic nerve diseases
Zhang et al. Leptin action on ARC‐PVN neural circuit regulates ejaculation behavior by altering sympathetic neuroplasticity
WO2025083211A1 (en) Use of factor h for the treatment of dementia
US20240115668A1 (en) Treatment of spinal cord injury with pten inhibitor
Siqueiros Márquez Regulation of dystrophin Dp71 during Müller glial cells edema in mouse retina= Regulación de la distrofina Dp71 durante el edema de las células gliales de Múller en la retina del ratón
Mdzomba The role of Nogo-A in the visual deficits induced by retinal injury
Hernández Pascual et al. SOCS1-derived peptide administered by eye drops prevents retinal neuroinflammation and vascular leakage in experimental diabetes
Márquez Regulation of dystrophin Dp71 during Müller glial cells edema in mouse retina
WO2025091016A1 (en) Compositions comprising p75ntr inhibitors and recombinant nerve growth factor and methods for the treatment of corneal diseases and disorders using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200323

R150 Certificate of patent or registration of utility model

Ref document number: 6681387

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees